patient

Aspaveli® (pegcetacoplan) approved in EU as orphan drug for treatment of PNH

Original Publication Date
Article Source
External Web Content
Published: Dec 15, 2021 STOCKHOLM, Dec. 15, 2021 /PRNewswire/ -- The first targeted C3 therapy approved in the EU Approval based on results from head-to-head PEGASUS phase 3 study where Aspaveli demonstrated superiority to eculizumab in improving haemoglobin levels1 Aspaveli will…

Andrew Brunner

Institution
Harvard Medical School
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
About
Dr. Andrew Brunner is an Assistant Professor, Medicine at Harvard Medical School and Assistant in Medicine at the Center for Leukemia at Massachusetts General Hospital in Boston, Massachusetts. His research is focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. He is involved in clinical trials for all stages of MDS with an overall goal of tailoring treatment to improve the outcomes of these patients.

ASTEX PHARMACEUTICALS PRESENTS OVERALL SURVIVAL DATA FROM ASCERTAIN PHASE 3 STUDY OF ORAL HYPOMETHYLATING AGENT INQOVI® (DECITABINE AND CEDAZURIDINE) IN MDS AND CMML AT INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES

Original Publication Date
Article Source
External Web Content
Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form…

AML Management: Feel Better With Food and Physical Activity

Original Publication Date
Article Source
External Web Content
If you’re receiving treatment for acute myeloid leukemia (AML), it probably feels like a lot of things are outside your control. But there are many small choices you can make each day — doable steps that can help you feel better inside and out. “It’s important to have achievable…

Eric Yang, MD

Institution
Ronald Reagan University of California, Los Angeles Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myeloproliferative Neoplasms (MPN)
About
Dr. Eric Yang is currently an Associate Clinical Professor of Medicine at the Ronald Reagan University of California, Los Angeles Medical Center. He obtained his undergraduate and medical degrees at the University of Illinois at Chicago College of Medicine, and completed his internal medicine residency and cardiology fellowship at Harbor-UCLA Medical Center, where he served as chief fellow. Since joining the academic faculty at UCLA as a clinician educator in 2011, he has been involved both in the invasive and noninvasive realms of the field, serving as one of the cardiology liaisons on the

Anthony Hunter, MD

Institution
Winship Cancer Institute of Emory University
Physician Status
accepting new patients
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Anthony M. Hunter, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A hematologist, Dr. Hunter specializes in treating patients with leukemia and other myeloid malignancies including myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Hunter holds professional memberships with American Society of Clinical Oncology, American Society of Hematology, and Society of Hematologic Oncology. Dr. Hunter received his Medical Degree from Medical College of Wisconsin in

"I Chose Life" - Debra Reflects on Three Years of Challenges with Aplastic Anemia

“Your blood counts are nearly nonexistent,” the doctor said. 

Before this moment, Debra considered herself to be generally healthy, just tiring easily.  She assumed the cause was the big project at work on top of a host of family and volunteer activities, or perhaps issues with her blood pressure. It was autumn of 2017.

Eunice Wang, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
About
Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang joined the Roswell Park faculty in 2003 and was appointed to the Leukemia Service of the Department of Medicine. She earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. She is
Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.